Sanofi pays Regeneron $1 billion upfront to expand immunology alliance
Sanofi and Regeneron expanded their immunology partnership to develop four next-generation, long-acting antibodies targeting type 2 inflammation, including one already in Phase 1 testing. Sanofi will pay Regeneron $1 billion upfront, with up to $7 billion in milestone payments; the companies will share development costs and future profits equally, while leaving Dupixent’s existing economics unchanged.
Business · 24 sources · 1dRead itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About dupilumab
Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13 receptor signalling, used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. It is also used for the treatment of eosinophilic esophagitis, prurigo nodularis and chronic obstructive pulmonary disease.
Everything about dupilumab →